ST Pharm
Seoul, KR
Program data pending ClinicalTrials.gov matching
· Last scored 2026-03-15
59.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (7)
Quick Facts: ST Pharm
- Signal Score
- 59.0/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- Seoul, KR
- Modalities
- Oligonucleotide, mRNA
- Active CGT Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesOligonucleotide, mRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
58.0
1 CGT manufacturing site: Seoul, KR
Modalities: Oligonucleotide, mRNA
Capacity assessment: 58.0/100
Sites: Seoul, KR
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
Recent Press7 articles
1 CGT manufacturing site: Seoul, KR
Modalities: Oligonucleotide, mRNA
Capacity assessment: 58.0/100
Recent News 7 articles
ST Pharm Signs Record 89.7 Billion Won Oligonucleotide Contract - Businesskorea
ST Pharm Signs Record 89.7 Billion Won Oligonucleotide Contract Businesskorea
ST Pharm lands record-breaking single CMO order worth KRW 89.7 billion from global pharmaceutical giant - 더바이오
ST Pharm lands record-breaking single CMO order worth KRW 89.7 billion from global pharmaceutical giant 더바이오
ST Pharm secures record oligo API deal with European drugmaker - CHOSUNBIZ - Chosunbiz
ST Pharm secures record oligo API deal with European drugmaker - CHOSUNBIZ Chosunbiz
ST Pharm Signs KRW 89.7 Billion Oligonucleotide Order, Largest Single Contract to Date - 아시아경제
ST Pharm Signs KRW 89.7 Billion Oligonucleotide Order, Largest Single Contract to Date 아시아경제
ST Pharm to produce non-clinical samples for Nipah virus mRNA vaccine - koreabiomed.com
ST Pharm to produce non-clinical samples for Nipah virus mRNA vaccine koreabiomed.com
ST Pharm Begins Production of Nipah Virus mRNA Vaccine Samples - 아시아경제
ST Pharm Begins Production of Nipah Virus mRNA Vaccine Samples 아시아경제
ST Pharm begins Nipah mRNA vaccine preclinical production in South Korea - CHOSUNBIZ - Chosunbiz
ST Pharm begins Nipah mRNA vaccine preclinical production in South Korea - CHOSUNBIZ Chosunbiz
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: